Sangamo BioSciences, Inc. Announces Presentation At ICAAC Of New Clinical Data Demonstrating Sustained Functional Control Of Viremia In Multiple HIV-Infected Subjects Treated With SB-728-T /PRNewswire/ -- Sangamo BioSciences, Inc. announced the presentation of new data demonstrating that a single infusion of Sangamo's novel ZFP Therapeutic , SB-728-T, resulted in sustained reduction and control of viral load in the absence of antiretroviral drugs in several subjects. In addition, a decrease in the size of the HIV reservoir, as demonstrated by measurement of HIV total DNA in peripheral blood mononuclear cells , was observed over a three year period in nine of nine subjects treated who remained on ART throughout the study.
http://ift.tt/1q7k5nk
http://ift.tt/1q7k5nk
No comments:
Post a Comment